Informazioni e Risorse sul Diabete
La collaborazione tra Sanofi e C-Path nel Type 1 Diabetes Consortium (T1DC) promette innovazioni nel trattamento e nella prevenzione del diabete di tipo 1, aprendo nuovi orizzonti nella ricerca farmaceutica.…
New research confirms for the first time that ethnicity is a risk factor for developing kidney disease in people with Type 1 diabetes. The study is one of the largest…
CHICAGO , 1 agosto 2022 /PRNewswire/ — COUR Pharmaceuticals, una società di biotecnologie in fase clinica che sviluppa nuove nanoparticelle immuno-modificanti (COUR NanoParticles o CNPs) progettate per riprogrammare il sistema…
Mitochondrial peptide MOTS-c regulates the immune system and prevents the self-destruction of cells that create insulin, according to a new study in mice A new study has shown that treating…
– Primary analysis data presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 Virtual Annual Meeting – – Primary endpoint assessing safety and tolerability met for both Phase 1b…